Technische Daten
Change(s) made: | Complete revision | Status: | In Vitro Diagnostic Use (IVD) | Spezies: | Rabbit | Ig Unterklasse: | IgG | Immunogen: | Ki-67 | Vorbehandlung: | ProTaqs® Antigen Enhancer I (Cat. No. 401602092) or ProTaqs® Antigen Enhancer IV (Cat. No. 401602392) | Zelluläre Lokalisation: | Nuclear | Kontrolle: | Tonsil, lymphoma | Synonyme: | Antigen identified by monoclonal antibody Ki 67, Antigen KI67, KIA, Ki-67, Ki67, MKI67, Proliferation related Ki 67 antigen. | Verfügbar in folgenden Ländern: | worldwide |
Beschreibung
Ki-67 is a nuclear protein expressed in all proliferating cells, which are in active phases of cell cycle (late G1, S, G2, mitosis). Ki-67 is not detected in resting cells (G0 phase). Thus, the antibody is a general proliferation marker, especially used to assess the proliferative activity of a tumor. Different cancer types express Ki-67, including breast, prostate, lung, and colon.
Literatur
[1] Bacus SS, Goldschmidt R, Chin D, Moran G et al. (1989): Biological grading of breast cancer using antibodies to proliferating cells and other markers. Am J Pathol. 135(5): 783-792. [2] Buhmeida A, Pyrhönen S, Laato M and Collan Y (2006): Prognostic factors in prostate cancer.
Diagn Pathol. 1: 4. [3] Soliman ML, Tiwari A and Zhao Q (2017): Coexisting tubular adenoma with a neuroendocrine carcinoma of colon allowing early surgical intervention and implicating a shared stem cell origin. World J Gastroenterol. 23(6): 1106-1112. [4] Kriegsmann M and Warth A (2016): Ki-67 expression in pulmonary tumors-reply. Transl Lung Cancer Res. 5(5): 552-553.
|